NCT01189812

Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Columbia Northwest Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.

Conditions

• Major Depressive Disorder
• Dysthymia
• Depression Not Otherwise Specified
• Borderline Personality Disorder

Interventions

Type	Name	Description
DRUG	Lithium Carbonate	300 mg one time per day for 4 weeks
DRUG	Placebo	Take one time daily for 4 weeks
DRUG	Citalopram	All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)

Timeline

• Start date: 2010-03-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2010-08-27
• Last updated: 2011-08-24
• Results posted: 2011-06-08

Locations

2 sites across 1 country: United States